Glucotrack, Inc. (GCTK) · Oct 28, 2026 · Other events
1-for-2 reverse split — Shares reduced from 2,368,237 to approximately 1,184,119
Glucotrack’s reverse split is now reflected in the filings, but the pro forma merger details highlight Lokahi control, bridge debt, and financing strain.
Glucotrack now sits behind a Lokahi-controlled clinical-stage biotechnology platform, while its legacy business remains an implantable continuous glucose monitor subsidiary. The reverse split itself changes the share count, not the business. The 1-for-2 split became effective October 23, 2026, began trading on a split-adjusted basis October 26, and left authorized shares unchanged at 250 million. 〔0〕 The company says shares outstanding fell from 2,368,237 to approximately 1,184,119, with proportional adjustments to options and warrants. 〔1〕 Because the split was already approved and effective before this filing, this is confirmation rather than a fresh strategic event.
| Pro forma combined figure | Amount | Filing context |
|---|---|---|
| Cash and cash equivalents | $10.6M | June 30, 2026 pro forma balance sheet |
| Total liabilities | $25.3M | June 30, 2026 pro forma balance sheet |
| Convertible notes at fair value | $11.7M | Bridge financings |
| In-process R&D and other identified intangibles | $25.4M | Lokahi purchase-price allocation |
| Goodwill | $15.6M | Lokahi purchase-price allocation |
| Aggregate merger consideration | $34.3M | 2,738,408 common-equivalent shares |
The filing’s more meaningful signal is the capital structure behind the pivot. Former Lokahi holders collectively receive 90% of the combined company’s equity, while the pro forma balance sheet carries $11.7 million of convertible notes and $1.1 million of warrant liabilities. 〔2〕 That makes this economically a Lokahi-led platform with Glucotrack’s legacy CBGM business retained inside it, not simply a clean continuation of the glucose-monitor story.
The financing buys runway but at a heavy cost. The two bridge financings generated $7.44 million of net cash, but carried a 22% original-issue discount, an 8% coupon, and $4.88 million of combined day-one losses before considering the additional $2 million interim PIPE. 〔3〕 The filing therefore does not add operating traction or clinical progress; it clarifies that the combined company remains dependent on financing while it develops Lokahi’s therapeutic assets and the CBGM subsidiary.
Bottom line: This is mostly a priced-in capital-structure filing, not a new operating catalyst. The split is cosmetic; the important takeaway is that control has shifted to Lokahi and the combined platform carries meaningful short-term financing pressure.
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!